Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.
Asako TanakaMasayuki HataMemiri TsuchikawaNaoko Ueda-Arakawa Ueda-ArakawaHiroshi TamuraManabu MiyataAyako TakahashiAi KidoYuki MuraokaMasahiro MiyakeSotaro OotoAkitaka TsujikawaPublished in: Clinical ophthalmology (Auckland, N.Z.) (2024)
Faricimab demonstrated significant effectiveness and safety in treatment-naïve nvAMD patients, particularly for PCV and PNV eyes. ELM presence and IRF is predictive of visual outcomes.
Keyphrases
- age related macular degeneration
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- vascular endothelial growth factor
- peritoneal dialysis
- optical coherence tomography
- type diabetes
- patient reported outcomes
- metabolic syndrome
- endothelial cells
- immune response
- skeletal muscle
- weight loss